Sponsored by
This is the results of the CUSP9v3 trial, and they are impressive. It was not controlled and is relatively small, but for patients with recurrent glioblastoma, the progression free survival rate at 12 months was 50%. This is a combination of older non cancer drugs, along with Temodar. All are easily available and relatively safe. May be worth trying both for newly diagnosed and recurrent Glioblastoma.